Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 21, 2022

SELL
$166.16 - $213.96 $1.66 Million - $2.14 Million
-9,994 Closed
0 $0
Q4 2021

Feb 02, 2022

BUY
$184.32 - $216.08 $2,764 - $3,241
15 Added 0.15%
9,994 $2.16 Million
Q3 2021

Oct 13, 2021

SELL
$179.86 - $214.88 $35,612 - $42,546
-198 Reduced 1.95%
9,979 $1.85 Million
Q2 2021

Jul 28, 2021

BUY
$170.47 - $211.93 $170 - $211
1 Added 0.01%
10,177 $1.83 Million
Q1 2021

Apr 29, 2021

BUY
$153.94 - $174.85 $28,478 - $32,347
185 Added 1.85%
10,176 $1.7 Million
Q4 2020

Jan 27, 2021

SELL
$101.87 - $151.79 $6,112 - $9,107
-60 Reduced 0.6%
9,991 $1.52 Million
Q3 2020

Oct 22, 2020

SELL
$99.9 - $121.13 $3,996 - $4,845
-40 Reduced 0.4%
10,051 $1.02 Million
Q2 2020

Jul 20, 2020

BUY
$92.74 - $125.82 $4,266 - $5,787
46 Added 0.46%
10,091 $1.22 Million
Q1 2020

May 01, 2020

SELL
$79.39 - $115.35 $2,778 - $4,037
-35 Reduced 0.35%
10,045 $953,000
Q4 2019

Jan 31, 2020

SELL
$78.31 - $95.34 $6,656 - $8,103
-85 Reduced 0.84%
10,080 $888,000
Q3 2019

Nov 08, 2019

SELL
$74.85 - $85.99 $12,724 - $14,618
-170 Reduced 1.64%
10,165 $811,000
Q2 2019

Jul 24, 2019

BUY
$76.06 - $120.81 $5,400 - $8,577
71 Added 0.69%
10,335 $807,000
Q1 2019

May 09, 2019

BUY
$107.15 - $126.84 $7,929 - $9,386
74 Added 0.73%
10,264 $1.21 Million
Q4 2018

Feb 06, 2019

BUY
$101.4 - $128.73 $91,260 - $115,856
900 Added 9.69%
10,190 $1.11 Million
Q2 2018

Jul 30, 2018

BUY
$101.14 - $118.31 $20,228 - $23,662
200 Added 2.2%
9,290 $1.05 Million
Q1 2018

May 09, 2018

SELL
$107.21 - $151.94 $64,325 - $91,164
-600 Reduced 6.19%
9,090 $1.02 Million
Q4 2017

Feb 01, 2018

BUY
$118.58 - $151.28 $9,486 - $12,102
80 Added 0.83%
9,690 $1.43 Million
Q2 2017

Aug 09, 2017

BUY
N/A
9,610
9,610 $1.25 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Chatham Capital Group, Inc. Portfolio

Follow Chatham Capital Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chatham Capital Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chatham Capital Group, Inc. with notifications on news.